Glaucoma technology includes studies of drugs and devices for ocular hypertension, open and closed angle glaucoma, pseudoexfoliative glaucoma and participation in national surgical outcomes database development.
Glaucoma Implant Device for patients with glaucoma who also need cataract surgery
Do You Qualify?
This research study is intended for individuals diagnosed with mild open angle glaucoma (OAG) in at least one eye, who also have a cataract eligible for surgery in the same eye. A new, investigational, surgically implanted medical device has been designed for permanent surgical implantation within the natural drainage canal of the eye. It is intended to reduce eye pressure by opening a passage to allow for fluid to flow from the front part of the eye to the existing drainage system.
For more information about this study, please contact us and we will be happy to talk with you in more detail to determine if you qualify.
The purpose of this study is to evaluate the safety and effectiveness of a new, surgically implanted medical device to reduce eye pressure in individuals diagnosed with mild open angle glaucoma. Eligible participants will also have a diagnosis of cataract eligible for surgical removal.
Summary of Study Procedures
Two pre-study evaluations are required to determine participant eligibility. Individuals who appear to qualify for participation after the first evaluation will be asked to discontinue all medications intended to lower eye pressure for a period of 5 days to 4 weeks, depending on the types of medications being used. This is called a washout period. Following the washout period, a second evaluation is completed to ensure that eye pressure is still within the appropriate range.
At that time, individuals who qualify for the study will be randomly assigned to one of two study groups. One group will be assigned to receive the investigational device in addition to cataract surgery. The other will be assigned to have cataract surgery only. There is an equal chance of being assigned to either group. Following the surgery visit, participants will complete 8 post-operative visits at defined intervals for the duration of 2 years.
Brief Eligibility Checklist
- Must be 18 years of age or older
- Diagnosis of mild open angle glaucoma (OAG) in at least one eye
- In the same eye, diagnosis of cataract eligible for surgical removal
- Currently using one to two medications in intended to lower eye pressure (maximum number of eye pressure medications is two)
- Must be able to complete a washout period, in which eye pressure lowering medications are discontinued
- No prior glaucoma surgery of any type
- Two evaluations to determine eligibility are required
- All visits must occur at our Minneapolis location with the exception of surgery, which may occur at our Bloomington location
- Eight post-operative follow-up examinations are required at: 1 day, 1 week, 1 month, 3 months, 6 months, 1 year, 18 months, and 2 years
Contact - email@example.com or call (612) 813-3607
Glaucoma Implant Device for patients with primary open angle glaucoma
Do You Qualify?
Glaucoma is a condition when the pressure within the eye increases to a level where it can damage the optic nerve, the area on the retina where light signals are transmitted to the brain and translated into images. Glaucoma is caused when the clear liquid inside the eye cannot flow continuously from the back part of the eye to the front. Damage to the optic nerve can result in decreased peripheral vision and eventually may lead to blindness. Glaucoma is the leading cause of irreversible blindness and affects millions of people worldwide.
The most common form of glaucoma is primary open angle glaucoma (POAG), which accounts for approximately 85% of all glaucoma cases. This condition does not typically exhibit any outward signs or symptoms. It develops gradually and can go undetected for years. Therefore, it is crucial to undergo thorough, routine eye examinations every year to monitor eye health and pressure.
In the early stages of POAG, medicated eye drops are usually prescribed to lower the eye’s pressure. Medications decrease the eye pressure, either by slowing the amount of fluid produced in the eye or by improving the flow through the drainage system. If the pressure is unable to be controlled with medications, surgery is recommended. Many different surgical devices and procedures are used to help stimulate the flow of fluid within the eye.
To qualify for this study you must have POAG in at least one eye that has failed to react well to conventional medical and surgical therapy. Please contact us and we will be happy to talk with you in more detail to determine if you qualify.
The purpose of this study is to evaluate the safety and effectiveness of an investigational implant device designed to help patients suffering from primary open angle glaucoma.
Summary of the Procedure
A pre-study evaluation is required to determine participant eligibility. Individuals who qualify for the study will have an implant device surgically inserted into one eye and will be followed for the duration of 1 year.
Brief Eligibility Checklist
- Must be 18 years of age or older.
- Diagnosis of primary open angle glaucoma (POAG) in at least one eye.
- Failed to react well to conventional medical therapy.
- Failed to react well to one conventional surgical procedure.
- No prior laser surgery of the retina.
- Not currently pregnant or planning to become pregnant during the study period.
- An evaluation to determine eligibility is required.
- All visits must occur at our Minneapolis location.
- Six postoperative, follow-up examinations are required at: 1 day, 1 week, 1 month, 3 months, 6 months, and 1 year.
Contact - firstname.lastname@example.org or call 612-813-3607
Study History- Glaucoma
Eye drop study for patients with elevated eye pressures
Randomized, double-masked, three treatment parallel group comparison of the fixed combination of latanoprost and timolol vs. latanoprost vs. timolol in glaucoma patients with optic nerve head abnormalities and visual field defects
Johns Hopkins glaucoma surgical outcomes study>
Clinical investigation of the AquaFlow collagen glaucoma drainage device randomized treatment protocol
A multicenter, double-masked, randomized, parallel, three-month study (with an extension to one year) of the safety, efficacy and acceptability of 0.15 and 0.2% Brimonidine-Purite compared with 0.2% Brimonidine administered three times daily in subjects with glaucoma or ocular hypertension
Six month study comparing Alphagan and Xalatan in subjects with chronic open angle glaucoma or ocular hypertension